ir.contravir.comContraVir Pharma @ContraVirPharma Twitter
ir.contravir.com Profile
ir.contravir.com
Maindomain:contravir.com
Title:ContraVir Pharma @ContraVirPharma Twitter
Description：The latest Tweets from ContraVir Pharma @ContraVirPharma ContraVir is a biopharmaceutical company focused on the clinical development of TXL™ and CRV431 to treat Hep B Edison NJ
Discover ir.contravir.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.contravir.com Information
| Website / Domain: | ir.contravir.com |
| HomePage size: | 78.297 KB |
| Page Load Time: | 0.851402 Seconds |
| Website IP Address: | 23.203.217.146 |
| Isp Server: | Akamai Technologies Inc. |
ir.contravir.com Ip Information
| Ip Country: | United States |
| City Name: | San Jose |
| Latitude: | 37.339389801025 |
| Longitude: | -121.89495849609 |
ir.contravir.com Keywords accounting
| Keyword | Count |
|---|
ir.contravir.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Security-Policy: report-uri //report-csp-violation |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1580716617" |
| From-Origin: same |
| Last-Modified: Mon, 03 Feb 2020 07:56:57 GMT |
| Link: http://ir.contravir.com/; rel="shortlink", http://ir.contravir.com/; rel="canonical", http://ir.contravir.com/investor-relations; rel="alternate"; hreflang="en", http://ir.contravir.com/investor-relations; rel="revision" |
| Server: nginx |
| X-Age: 0 |
| X-Content-Security-Policy: report-uri //report-csp-violation |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Generator: Drupal 8 (https://www.drupal.org) |
| X-Request-ID: v-c012146e-465a-11ea-a093-9f0562e48de9 |
| X-UA-Compatible: IE=edge |
| X-WebKit-CSP: report-uri //report-csp-violation |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 14029 |
| X-EdgeConnect-MidMile-RTT: 40 |
| X-EdgeConnect-Origin-MEX-Latency: 631 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Mon, 03 Feb 2020 07:56:57 GMT |
| Date: Mon, 03 Feb 2020 07:56:57 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: SimpleSAMLSessionID=ac973e316de9bca7b3cb97cd8429ce69; path=/; secure; HttpOnly, DrupalVisitorMobile=0; path=/ |
ir.contravir.com Meta Info
| charset="utf-8"/ |
| content="Investor Relations | Hepion Pharmaceuticals, Inc." name="title"/ |
| content="Hepion Pharmaceuticals, Inc." property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="no-referrer" name="referrer"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
23.203.217.146 Domains
| Domain | WebSite Title |
|---|
ir.contravir.com Similar Website
| Domain | WebSite Title |
|---|---|
| ContraVir Pharma @ContraVirPharma Twitter | |
| Future Pharma 2020 | Pharma Marketing & Sales Conference | |
| Future Pharma 2020 | Pharma Marketing & Sales Conference | |
| Pharma Marketing How to Successfully Market in the Pharma | |
| Asia Pharma 2020 | Pharma Conferences 2020 | Pharma Congress 2020 | Pharmaceutical Conferences | Sin | |
| Pharmaceutical Conferences | Pharma Conferences | Top Pharma Conferences 2020 | Drug Conferences | P | |
| Home - Getz Pharma - Getz Pharma | |
| Top Pharma Conferences 2020 | Pharma Conference 2020 | Pharmaceutical Conferences | Pharmaceutical S | |
| Online Pharma | |
| Biotech & Pharma | |
| LEO Pharma | |
| Pharma Citeline | |
| Aristo Pharma | |
| Synergy Pharma - | |
| Pharma CI Conference and Exhibition: Welcome |
ir.contravir.com Traffic Sources Chart
ir.contravir.com Alexa Rank History Chart
ir.contravir.com Html To Plain Text
Skip to main navigation Home About Company Overview Executive Team Board of Directors Scientific Advisory Board Partnering Liver Disease Overview Non-Alcoholic SteatoHepatitis (NASH) Hepatocellular Carcinoma (HCC) Viral Hepatitis Pipeline Drug Candidates CRV431 Therapeutic Strategy Clinical Trials News Press Releases Hepion in the News Presentations Publications Investors Overview News Releases Events Presentation Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Financials & Filings SEC Filings Fundamentals Annual Reports & Proxy Statements Corporate Governance Documents & Charters Management Team Board of Directors Committee Composition Investor Resources Investor FAQs Email Alerts Contact IR RSS Feeds Search Investors Contact Contact Us Careers Press enter to begin your search Main navigation Home About Company Overview Executive Team Board of Directors Scientific Advisory Board Partnering Liver Disease Overview Non-Alcoholic SteatoHepatitis (NASH) Hepatocellular Carcinoma (HCC) Viral Hepatitis Pipeline Drug Candidates CRV431 Therapeutic Strategy Clinical Trials News Press Releases Hepion in the News Presentations Publications Investors Overview News Releases Events Presentation Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Financials & Filings SEC Filings Fundamentals Annual Reports & Proxy Statements Corporate Governance Documents & Charters Management Team Board of Directors Committee Composition Investor Resources Investor FAQs Email Alerts Contact IR RSS Feeds Search Investors Contact Contact Us Careers Investor Relations Hepion is a biopharmaceutical company focused on the development and commercialization of targeted therapies for liver disease arising from chronic hepatitis B, C and D virus (HBV, HVC, HDV) and non-alcoholic steatohepatitis (NASH). Price: Investor Relations Corporate Profile Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431’s potent inhibition of cyclophilin enzymes, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. For more information, please visit www.hepionpharma.com . News Releases Summary Toggle Summary Toggle Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference Summary Toggle September 4, 2019 Summary Toggle EDISON, N.J. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today Summary Toggle Summary Toggle Summary Toggle Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Summary Toggle September 3, 2019 Summary Toggle EDISON, N.J. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today Summary Toggle Summary Toggle Summary Toggle Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431 Summary Toggle August 14, 2019 Summary Toggle Study Represents the Third and Final Stage of CRV431’s Streamlined Early Clinical Program EDISON, N.J. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease Summary Toggle Latest Events Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference Sep 10, 2019 at 4:15 PM EDT Click here for webcast ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference May 2, 2019 at 1:30 PM EDT Listen to webcast Latest Form 10-K Mar 14, 2019 View HTML 0001104659-19-014652.pdf 0001104659-19-014652.rtf 0001104659-19-014652.xls EX-101.INS - XBRL INSTANCE DOCUMENT Latest Form 10-Q Nov 14, 2019 View HTML 0001104659-19-064342.pdf 0001104659-19-064342.rtf 0001104659-19-064342.xls EX-101.INS - XBRL INSTANCE DOCUMENT Latest Proxy Statement Apr 02, 2019 View HTML 0001104659-19-019408.pdf 0001104659-19-019408.rtf 0001104659-19-019408.xls Contact IR Stephen Kilmer Investor Relations Phone: 646.274.3580 Email: skilmer@contravir.com Get Important News and Updates by Email Subscribe © 2020 Hepion Pharmaceuticals, Inc. | Disclaimer & Terms of Use...
ir.contravir.com Whois
"domain_name": [
"CONTRAVIR.COM",
"contravir.com"
],
"registrar": "GoDaddy.com, LLC",
"whois_server": "whois.godaddy.com",
"referral_url": null,
"updated_date": [
"2019-01-23 14:26:54",
"2019-01-23 14:26:52"
],
"creation_date": "2013-05-16 02:46:43",
"expiration_date": "2024-05-16 02:46:43",
"name_servers": [
"NS01.DOMAINCONTROL.COM",
"NS02.DOMAINCONTROL.COM"
],
"status": [
"clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited",
"clientRenewProhibited https://icann.org/epp#clientRenewProhibited",
"clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited",
"clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited http://www.icann.org/epp#clientUpdateProhibited",
"clientRenewProhibited http://www.icann.org/epp#clientRenewProhibited",
"clientDeleteProhibited http://www.icann.org/epp#clientDeleteProhibited"
],
"emails": "abuse@godaddy.com",
"dnssec": "unsigned",
"name": null,
"org": "ContraVir Pharmaceuticals, Inc",
"address": null,
"city": null,
"state": "New Jersey",
"zipcode": null,
"country": "US"